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Patients experience a number of complications after
hematopoietic cell transplantation (HCT), including failure to
recover neutrophil or platelet counts, acute or chronic graft-
versus-host disease (GVHD), and disease relapse. Such
complications, as well as other factors, may lead to death.
Accurate modeling of the likelihood of these complications
can provide insight into the recovery process after HCT and
guide clinical monitoring. Multistate models are a useful tool
fordescribing theposttransplantation recoveryprocess. In this
article, we review several key applications of multistate
models and illustrate themusing a dataset from the Center for
International Blood and Marrow Transplant Research with
outcomes after unrelateddonorBMT in375patientswith SAA.OVERVIEW OF MULTISTATE MODELS
In a multistate model, the state X(t) represents a patient’s
clinical status at a particular time point t posttransplantation
from among a set of possible states, and the lines between
the states indicate transitions between states that can occur
with a particular rate. Andersen and Keiding [1] provided an
introduction into event history analysis through multistate
models. As an example, consider the dataset of outcomes
after BMT for patients with SAA. One concern after trans-
plantation is that the donor cells will fail to engraft and
repopulate the recipient’s immune system; this can manifest
as either lack of initial engraftment or recovery of neutro-
phils, or as secondary graft failure when the patient’s
neutrophil counts drop after initial recovery. This process can
be shown in a multistate model, where a patient starts
posttransplantation in state 0 (alive without neutrophil
recovery), and from there can either go to state 1 (alive with
neutrophil recovery) or die before engraftment (state 2).
Once the patient is in state 1, he or she can die or can
experience secondary graft failure (state 3), and from state 3
the patient can further progress to death. This multistate
model is summarized in Figure 1, which also shows the
numbers of patients experiencing each transition, as well as
the number at risk.
Some states are absorbing states, from which it is not
possible to transition out, whereas the remaining ones are
transient states; in this example, only state 2 is an absorbing
state. Note that survival data and competing-risks data are
both special cases of multistate models. For survival data,
there is one absorbing state (death) and one transient stateFinancial disclosure: See Acknowledgment on page S87.
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one transient state (alive and failure-free). Models for
survival data and competing-risks data have been reviewed
for a clinical BMT audience by Klein et al. [2] and Logan et al.
[3], and we do not discuss them further here; rather, we
focus on the utility and applications of more complex
multistate models.
A multistate model is often described by the transition
intensities or rates, hij(t). These values indicate a patient’s
likelihood of being in state j tomorrow given that he or she is
in state i today (at time t posttransplantation). Alternatively,
interest may lie in describing the probability of being in state
j at time t given that the patient is in state i at time s, denoted
by Pij(s,t). This probability is a function of the transition
intensities for all possible paths between the two states, and
it also accounts for the time interval between s and t. Finally,
interest may lie in describing the probability of being in
a particular state j at a particular time t posttransplantation.
This is given by the state probability PjðtÞ ¼ P0jð0; tÞ, where
state 0 refers to the immediate posttransplantation state.
Multistate models are often assumed to have a Markov
property, meaning that the transition intensity hij(t) depends
only on the patient’s history through the state which he or
she is in at the time t, X(t). Less-restrictive assumptions
include semi-Markov models, in which the transition
intensity depends on the amount of time spent in that state,
or non-Markov models, in which the transition intensity
depends on the entire path taken to reach the current state.
MODELING COVARIATE EFFECTS
Often researchers are interested in understanding the
effects of covariates on posttransplantation outcomes. The
effect of covariates can be modeled in various ways. An
Andersen-Aalen-Johansen Markov model assumes that each
transition rate can be modeled using a Cox proportional
hazards model,
hijðt j ZÞ ¼ h0ijðtÞexpðbZÞ;
so that the effect of covariate Z on a particular transition rate
can be interpreted as a hazard ratio, exp(b). Note that a Cox
model must be estimated for each transition, which may
be difﬁcult to do, particularly for modest-sized datasets.
Sometimes simplifying assumptions aremade to stabilize the
models by pooling the data across several transitions. One of
these assumptions is particularly common when analyzing
the effect of a time-dependent covariate, such as whether the
patient has experienced GVHD, on a subsequent outcome,
such as relapse. Here the transitions into the relapse state
from a state with GVHD and a state without GVHD areTransplantation.
Figure 1. Multistate model for engraftment, secondary graft failure, and death
after BMT for SAA.
Figure 2. Probability of being alive with neutrophil recovery as a function of
time posttransplantation.
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another, so that the transition intensity into the relapse state
simply depends on whether or not GVHD occurs by time t,
hRðt j ZÞ ¼ h0RðtÞexpfbZ þ gIðTGVHD  tÞg;
where IðTGVHD  tÞ is 1 if the patient has experienced GVHD
before time t and 0 otherwise. The hazard ratio for relapse in
a patient who has experienced GVHD compared with
a similar patient (same covariate Z) who has not experienced
GVHD is given by exp(g).
Alternatively, interest may lie in the effect of covariates on
the transition probabilities or state probabilities rather than
in the transition rates. One approach to studying this effect is
to combine the various Cox models for each transition into
a combined model for the transition probability; however,
the effect of the covariate in such a model is complex and
difﬁcult to interpret. Alternatively, a number of researchers
have proposed methods for direct modeling of state proba-
bilities, including pseudovalue regression [4] and direct
binomial regression [5]. In both cases, the state probability is
assumed to be related to the covariates through a link
function, g($), so that gðPjðtÞÞ ¼ bZ.
To estimate the parameters using pseudovalue regression,
ﬁrst estimate the probability of being in state j at time t for
the complete dataset, denoted by bPjðtÞ, and the state prob-
ability on the dataset obtained by deleting patient i, denoted
by bP
ðiÞ
j ðtÞ. Then the pseudovalue estimate of the state
probability for patient i at time t is given by the difference,
YijðtÞ ¼ nbPjðtÞ  ðn 1ÞbP
ðiÞ
j ðtÞ. When there is no censoring,
Yij(t) reduces to a simple indicator of whether the ith subject
is in state j at time t. State probabilities can be estimated
using the product integral relationship between transition
rates and state probabilities; alternatively, for transient
states, Pepe [6] proposed writing the state probability as
a difference in Kaplan-Meier estimates (see Andersen and
Klein [7] for details).
Once these pseudovalues are computed for each indi-
vidual and time point on a prespeciﬁed grid of time points,
they are used as the dependent variables in the foregoing
model to examine the effects of covariates on outcomes.
Parameter estimates and standard errors are obtained using
generalized estimating equations [8], and may be computed
using, for example, the SAS procedure GENMOD.
Although many choices of the link function are possible,
we mention 3 of these choices here. First, the logistic linkfunction gðxÞ ¼ logðx=ð1 xÞÞ gives results analogous to
logistic regression, so that we can interpret exp(b) for
a binary covariate as the odds ratio for the likelihood of being
in state j at time t for patients with the factor versus those
without the factor. Alternatively, a complementary log-log
link function, gðxÞ ¼ logðlogðxÞÞ, and an identity link
function, g(x) ¼ x, are often considered as well.
This approach of direct modeling of state probabilities has
been described to model the current leukemia-free survival
probability [7], as well as other probabilities in an illness-
death model in which acute GVHD is the transitional illness
[4]. Here we apply it to the SAA example described in the
previous section. One outcome that may be of direct interest
to clinicians is the probability of being alive and engrafted
(state 1) as a function of time; this combines both primary
recovery and secondary graft failure into a single summary
endpoint describing a positive result. Note that the proba-
bility of being in state 1 can be written as the probability of
being in state 0 or 1 minus the probability of being in state 0.
Thus, an estimate of the probability of being alive and
engrafted is provided by a difference in the Kaplan-Meier
estimates,
bP1ðtÞ ¼ bS2;3ðtÞ  bS1;2ðtÞ;
where bS2;3ðtÞ is the Kaplan-Meier estimate treating transi-
tions to state 2 or state 3 as events and bS1;2ðtÞ is the Kaplan-
Meier estimate treating transitions to state 1 or state 2 as
events. An estimate of the marginal probability of being alive
and engrafted is given in Figure 2.
The pseudovalue for P1(t) is obtained using the delete-1
estimator as
Yi1ðtÞ ¼ nbP1ðtÞ  ðn 1ÞbP
ðiÞ
1 ðtÞ:
These pseudovalues can be used to directly model the
probability of being alive and engrafted as a function of
covariates, including age at transplantation, sex, Karnofsky
performance score, donorerecipient HLA matching, and
GVHD prophylaxis. Pseudovalues at 3 time points (3, 6, and
12months) and a logistic link functionwere used. The results
of the regression model for survival with engraftment in
terms of odds ratios for each of these covariates is given in
Table 1. HLA mismatch is signiﬁcantly associated with worse
Table 1
Pseudovalue Regression Model for the Probability of Being Alive with Engraftment
Variable Comparison Odds Ratio 95% Conﬁdence Interval P Value
Age 21-40 years versus 20 years 2.06 (1.16-3.66) .014
>40 years versus 20 years 0.73 (0.34-1.56) .418
Sex Male versus female 1.47 (0.91-2.38) .114
Karnofsky Performance Score <90 versus 90 1.67 (0.96-2.92) .070
Unknown versus 90 1.45 (0.48-4.36) .506
HLA match Mismatched versus matched 0.50 (0.31-0.79) .003
GVHD prophylaxis FK06-based versus cyclosporine A þ methotrexate 0.96 (0.55-1.69) .893
Others versus cyclosporine A þ methotrexate 0.71 (0.36-1.39) .315
B.R. Logan / Biol Blood Marrow Transplant 19 (2013) S84eS87S86survival with engraftment, and patients aged 21-40 have
signiﬁcantly better survival with engraftment compared
with those aged 20 years or >40 years. Other risk factors
are not signiﬁcantly associated with the probability of being
alive with neutrophil recovery.0 2 4 6 8 10 12
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Figure 3. Probabilities of dying within 2 years for patients in various states at
each landmark time point.PREDICTION AND LANDMARK ANALYSIS
Another important use of multistate models is to provide
predictions of how a patient’s prognosis may change over
time as he or she transitions through different states. Klein
and Shu [9] used multistate models to describe how the
probability of dying in remission within 2 years can be pre-
dicted based on whether a patient exhibits platelet recovery
and/or acute GVHD by a particular time. They also illustrated
the notion of innovation gain, the difference in predicted
probabilities between patients in 2 states, which reﬂects the
effect of a speciﬁc condition on outcome. Van Houwelingen
and Putter [10] proposed a simpliﬁed model for obtaining
long-term survival predictions based on a patient’s status at
various landmark times. At each landmark time, s, the model
assumes a proportional hazards model for the risk of death at
subsequent times given the patient’s current status X(s), for
example, alive with or without platelet recovery and with or
without previous acute GVHD,
hðt jXðsÞ; sÞ ¼ h0ðt j sÞexpfbðsÞXðsÞg:
Because the parameters are expected to vary slowly over
the landmark times, the baseline hazard function, h0ðt j sÞ,
and the log hazard ratio, b(s), are modeled as smooth func-
tions of the landmark time s. The data for each landmark
time can then be stacked on top of one another in the dataset,
and standard software that allows delayed entry can be used
to estimate the model parameters.
For the SAA example, we use the landmarking method of
Van Houwelingen and Putter [10] to calculate the probability
of 2-year mortality for patients alive and in each of the three
states at various landmark times posttransplantation. The
curves in Figure 3 refer to a patient aged 20 years with
a Karnofsky Performance Score90 and HLA-matched to the
donor. Note that few patients are alive and in state 0 more
than 1 month posttransplantation, and so this state is not
particularly informative for such a landmark analysis.
However, the plot shows that the probability of dying by
2 years for a patient who is alive with neutrophil recovery at
3 months posttransplantation is <20%, compared with >50%
for a patient who is alive but has experienced secondary graft
failure. At 6 months, the probability of dying by 2 years
posttransplantation changes to 10% for patients without
secondary graft failure and 35% for those with secondary
graft failure. These plots help attach a clinical interpretation
to the impact of secondary graft failure on long-term
outcome to augment hazard ratios from a model.OTHER APPLICATIONS OF MULTISTATE MODELS
Multistate models have been used in various other
settings with BMT applications. For example, Lee et al. [11]
and Cutler et al. [12] used Markov multistate models to
facilitate decision analysis regarding allogeneic HCT versus
no HCT for patients with chronic myelogenous leukemia and
myelodysplastic syndrome (MDS), respectively. Cutler et al.
considered several transplantation strategies, including the
decision of whether to proceed directly to BMT or to proceed
only after progression to acute myelogenous leukemia
(AML). Patient health states included alive with MDS, alive
with AML, BMT, alive after BMT, AML or MDS relapse, and
death [12]. For these kinds of decision analyses, several data
sources are typically needed to estimate the various transi-
tions present, particularly given that these transitions may
occur before or after transplantation. The merging of
different data sources raises questions about potential
selection bias for the transplantation and nontransplantation
data. Once the transition rates for the model are estimated,
mean life years and quality-adjusted life years can then be
compared among the different strategies.
Quality-adjusted life years have been studied as a
multistate model in other settings as well. For example,
Tunes da Silva and Klein [13] proposed using pseudovalues to
ﬁt direct regression models for mean quality-adjusted life
years.
Another application of multistate models is estimation of
the prevalence of a particular intermediate condition among
survivors. For example, Klein and Shu [9] discussed various
methods of estimating the prevalence of chronic GVHD at
time t, deﬁned as the probability that a subject has chronic
GVHD at time t given that the subject is alive at time t.
B.R. Logan / Biol Blood Marrow Transplant 19 (2013) S84eS87 S87CONCLUSION
Multistate models provide a ﬂexible framework for
understanding clinical events occurring posttransplantation
and their impact on outcome. They can be used to estimate
and model clinically relevant quantities, such as current
leukemia-free survival or the probability of being alive with
engraftment, as well as to provide information on how
a patient’s current state affects his or her long-term prog-
nosis. However, they do require a greater level of detail in
data collection owing to the number of transitions between
states that need to be captured. They also may require larger
sample sizes to model various transitions adequately. These
caveats aside, recent statistical techniques developed for
multistate models have helped make this a promising area of
clinical research in BMT.
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